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Summary 
Syrian golden hamsters when allowed free access to food and an exercise wheel 
will run long distances and develop hyperphagia and accelerated linear body growth 
with high circulating levels of growth hormone and insulin. Somatostatin, a widely 
distributed brain-gut neurohormonal peptide, modulates nutrient absorption and 
may regulate food intake. To examine the role of circulating plasma somatostatin- 
like immunoreactivity (SRIF-LI; pg/ml) in exercise induced hyperphagia 4 groups of 
animals were studied; an unrestricted exercise group (279.0 + 107.7, n = 10); a 
sedentary group (121.1 + 40.8, n = 8); a restricted exercise group (107.7 + 12.4, n 
= 6); and a restricted no exercise group (115.5 + 45.9, n = 9). Thus, the unrestricted 
exercise group has a significantly elevated SRIF-LI concentration (P < 0.01) while 
there was no difference between the other 3 groups. The elevation of plasma SRIF- 
LI in the unrestricted exercise group may represent a response to modulate increased 
nutrient entry in this group or may represent an incompletely effective satiety signal. 
Hyperphagia; Accelerated growth; Somatostatin 
Introduction 
Syrian golden hamsters, allowed free access to food and an exercise wheel, will run 
long distances at night which induces a syndrome of hyperphagia and accelerated 
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linear body growth [1]. These hyperphagic growing animals have high circulating 
levels of growth hormone due to increases in pulse frequency and amplitude [2] and 
of insulin [1] which may mediate the accelerated linear growth. When exercising with 
restricted access to food, linear growth [1] and cellular proliferation of the distal 
femoral epiphyseal growth zone is blocked [3]. 
Somatostatin (somatotrophin release inhibiting factor, SRIF), was initially extract- 
ed from the hypothalamus and acts within the hypothalamic-pituitary portal venous 
system as a true hormonal regulator of growth hormone secretion [4,5]. It has since 
been found to have a far wider tissue distribution and probably serves multiple func- 
tions [6,7]. These include: (a) presence in neurons of many areas of the brain, spinal 
cord and peripheral nervous system where it is a putative peptidergic neurotrans- 
mitter/neuromodulator [6,8]; b: widespread distribution throughout the gut [6,8] 
where it is distributed in the intrinsic autonomic neurons and in mucosal endocrine 
cells [6,8], where it is believed to act as a paracrine transmitter and, within the visceral 
portal system, as a hormone [9,10]. SRIF's actions on the gut include suppression of 
many gut hormones including gastrin, secretin and CCK; reduction of gastric secre- 
tion, reduction in pancreatic-exocrine secretion, reduced gut motility, and delayed 
nutrient absorption [5,11-14]; c: within the pancreas the majority of SRIF is present 
in the ~ cells of the islets [6,8] where it appears to act as a paracrine transmitter or 
to transmit a signal by intimate cell-to-cell contact via tight junctions. Its action here 
is to reduce insulin and glucagon secretion [12]. It also enters the portal system where 
it may act as a hormone [9,10,15]. 
We examined somatostatin-like immunoreactivity (SRIF-LI) in the general cir- 
culation of exercising hyperphagic animals and appropriate controls to test the hy- 
pothesis that this state with its striking alteration in nutrient ingestion, growth and 
activity, may be associated with alterations in circulating SRIF-LI. 
Materials and Methods 
Female golden hamsters (Mesocricetus auratus Waterhouse) over 10 weeks old and 
weighing 90-100 g (Eagle Laboratory Animals, Farmersburg, IN) were individually 
housed under conditions of constant temperature (22°C and a 12 h light/dark cycle 
with continuous access to tap water ad lib. Animals were divided into 4 experimental 
groups of 10 [1,3]: 
(a) Unrestricted exercise group. Animals were allowed free access to an unlimited 
supply of Purina Chow Formulab 5008 and to a horizontal exercise wheel. 
(b) Sedentary group. Animals were allowed free access to unlimited supply of 
Purina Chow Formulab 5008 without an exercise wheel. 
(c) Restricted exercise group. Animals were allowed free access to an exercise wheel 
but food intake was restricted to the quantity consumed by the sedentary group. 
(d) Restricted no exercise group. Animals were not allowed access to the exercise 
wheel and food intake was restricted to a point where no weight gain occurs. 
The disk exerciser was a freely turning perspex disk 23-25 cm in diameter, the 
revolutions of which could be electrically recorded [1,3]. 
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Animals were weighed daily and the ponderal growth calculated for the experi- 
mental period. Animals were sacrificed in random order by decapitation during the 
second hour of the daylight cycle. Trunk blood was collected into chilled glass tubes 
containing Trasylol (aprotinin 5000 KIU/ml) and EDTA to yield a 10:1 ratio (4 ml 
of blood). The plasma was immediately separated by centrifugation and stored in 
aliquots at -20°C until assay. 
Somatostatin-like immunoreactivity (SRIF-LI) was determined in unextracted 
plasma by a radioimmunoassay using an antiserum (Cape Town 1374) raised in a 
rabbit to synthetic cyclic SRIF-(1-14) conjugated to whelk hemocyanin by the car- 
bodiimide reaction [16-18]. The antiserum has been shown to be specific for the 6- 
11 region of SRIF-14. It has 75% cross-reactivity with SRIF-(1-25) and a 60% 
cross-reactivity with SRIF-(1-28) [18]. [Tyrl]SRIF was radiolabeled by the chlora- 
mine-T technique with 12Siodine and the tracer was purified by ion exchange chro- 
matography on CM-52 cellulose to a specific activity of ca. 750 Ci/mol. The standard 
was synthetic cyclic somatostatin-(1-14) (Ayerst AY 24910, Ayerst Laboratories, 
Rouses Point, NY). The assay was performed in 50 mM ammonium acetate buffer 
at a pH of 5.6 [19]. This low pH has been shown to permit the assay of SRIF-LI in 
rat [10] and human [16] plasma without extraction. Separation of antibody-bound 
from unbound tracer was achieved by the use of dextran-coated charcoal. The limit 
of sensitivity (2 standard deviations above assay buffer control tubes) was 2 pg/tube. 
The intra-assay coefficient of variation was 5% and the interassay coefficient of vari- 
ation was 12%. 
Plasma samples were assayed in triplicate in 3 dilutions to determine parallelism 
of plasma SRIF-LI with the standard curve. Recovery of standard somatostatin from 
plasma was determined by the addition of 500 ng/ml of synthetic cyclic SRIF-(1-14) 
to aliquots of hamster plasma and serially diluting with SRIF-free plasma. Non- 
specific binding of the 125I.[Tyrl]SRI F with hamster plasma resulted in no more than 
5% damage to the label as determined by chromatoelectrophoresis. Plasma SRIF-LI 
concentrations were expressed as pg SRIF-(I-14) equivalents/ml. 
Statistical methods 
Overall differences between the 4 groups were determined using the Welch statistic 
for one-way analysis of variance. Multiple pairwise comparisons to determine sig- 
nificance at the P = 0.01 level were made using the Bonneferroni correction method 
[20]. 
Results 
The mean body weights for the 10 animals in each experimental group are shown 
in Fig. 1 which shows that the exercising group had the typical accelerated growth 
when compared to the sedentary controls while the exercising restricted and sedentary 
restricted groups showed minimal growth. 
The mean plasma SRIF-LI concentrations for all 4 groups of animals are presented 
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Fig. 1. Changes in weight in the 4 groups of  hamsters. The first arrow indicates the start of  the experiment 
and the second arrow the time of sacrifice. Rest, food-restricted; Sed, sedentary; Ex, exercise. 
TABLE I 
Plasma-SRIF-LI concentrations in the 4 groups of  animals (individual data) pg/ml 
Unrestricted Unrestricted Restricted Restricted 
exercise sedentary exercise sedentary 
Mean (pg/ml) 
4- S.D. 
Mean weight (g) 
302.9 179.7 92.4 178.8 
500.5 155.4 121.6 78.0 
312.9 138.1 91.8 183.0 
161.5 120.7 109.7 112.4 
304.9 137.1 119.3 43.9 
164.5 52.4 111.4 106.2 
346.2 102.3 129.7 
216.1 83.7 127.5 
155.1 79.7 
325.5 
279.0* 121.2"* 107.7"* 115.5"* 
4- 107.7 +40.8 + 12.4 +45.9 
139 118.5 99.5 95 
* Unrestricted exercise greater than all 3 other groups, P < 0.01. 
** No significant differences between unrestricted sedentary restricted exercise and restricted sedentary 
groups. 
significant (P < 0.01) elevation of plasma SRIF-LI when compared to be sedentary 
groups and exercising food-restricted hamsters. Plasma SRIF-LI in the latter 3 
groups did not differ significantly. (The F-value for the overall main effect was 13.54.) 
D i s c u s s i o n  
If adult golden hamsters in the slow asymptotic phase of growth are given the 
opportunity to exercise on horizontal exercise disks, they voluntarily engage in high 
levels of physical activity and re-enter the exponential phase of linear and ponderal 
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growth throughout their exposure to such exercise. The linear growth is possible as 
the epiphyseal growth plates remain open in adulthood. This phenomenon is as- 
sociated with marked hyperphagia and the growth may be inhibited entirely by re- 
stricting nutrient intake to the level of sedentary controls [1]. The exercise induced 
hyperphagia is associated with increased circulating levels of growth hormone and 
insulin [1] which may act, probably through the mediation of somatomedin, to induce 
accelerated growth. Increases in circulating growth hormone (GH) are a consequence 
of a doubling of GH pulse frequencies and amplitude [2]. Exercise-induced facilita- 
tion of pulsatile GH release is mediated by release of endogenous opiates which 
appear to restrain the action of endogenous somatostatin [2]. Which may have been 
increased in parallel with peripheral blood SRIF-LI. 
The ingestion of an increased amount of food in the exercising animals is associated 
with a striking elevation in the plasma SRIF-LI levels. Exogenously administered 
SRIF reduces gastrin levels, gastric acid a~nd enzyme output, delays gastric emptying, 
reduces pancreatic exocrine secretion, reduces gastrointestinal motility and slows nu- 
trient absorption [5,11-14]. SRIF also decreases pancreatic endocrine secretion of 
insulin and glucagon [12] and gut peptide secretion [12,14]. These effects, coupled 
with the fact that nutrient ingestion releases gastrointestinal [15,21,22] and pancreatic 
endogenous SRIF-LI [15,22] has led to the postulate that SRIF-LI acts physiologi- 
cally to modulate and slow the absorption of nutrients from the gut and modulates 
the hormonal response to absorbed nutrients [16,17,23-25]. 
The source of the elevated SRIF-LI in the general circulation of the exercising 
animals is probably the gut and pancreas which is the site of the largest proportion 
of SRIF [6-9,18,36] containing tissues and furthermore is a site from which nutrients 
are known to cause such release [15,17,19,22-25]. The assay utilized measures of 
SRIF-(1-14) as well as SRIF-(I-25) but the relative proportions of the various 
subforms of SRIF-LI [17,26] was not further investigated. The SRIF-LI concentra- 
tions measured in unextracted plasma by this assay [10,19,34] are higher by a factor 
of 3 or greater than in techniques utilizing extraction [21,23,24,33]. Nevertheless, the 
relative concentration in different parts of the circulation and the responses to nu- 
tritional and other stimuli are consonant with the findings of others using extraction 
[10,19,21,23,24,26, 37]. 
The hypothalamic pituitary portal SRIF is unlikely to contribute to the marked 
increase in SRIF-LI in the general circulation as the degree of dilution of hypoth- 
alamic portal blood has been shown to preclude this [9,19]. In addition, the elevated 
growth hormone levels with evidence that in exercising animals endogenous opiates 
restrain endogenous somatostatin action on GH release [2] militate against inhibition 
by this component of circulating SRIF-LI. These concentrations of SRIF-LI are sim- 
ilar to those occurring following meal ingestion in man and other animals [15- 
17,22,37] and are of a magnitude which has been shown when infused exogenously 
to reduce nutrient absorption and pancreatic exocrine function [1,5,11-14]. 
Nutrient ingestion is a major stimulus to SRIF-LI secretion and somatostatin is 
believed to regulate or modulate nutrient absorption from the gut [22,23,25,35]. In 
the exercise induced hyperphagic state, increased food ingestion might provide an 
exaggerated stimulus and thus may explain the striking increase in circulating SRIF- 
90 
LI [22,23,25]. Once amino acids and other nutrients are absorbed these also act as 
a stimulus to SRIF-LI release from the pancreas and gut [15,19,21,23-25]. In addition 
somatostatin has been shown to induce satiety and thus may serve to modulate nu- 
trient ingestion [29,30,32] in a negative feedback loop. The exercise induced hyper- 
phagia may thus activate counter-regulatory SRIF-LI secretion to modulate the nu- 
trient ingestion (albeit that this satiety signal is at best only modestly effective as 
evidenced by the ongoing hyperphagia). To determine if the elevated circulatory SRIF- 
LI levels are the consequence of exercise (by means of the hyperphagia it induces) 
or to the hyperphagia per se it would be necessary to examine SRIF-LI levels in other 
hyperphagic models, such as the gold thioglucose mouse, the Zucker rat or, the Ob 
Ob mouse. 
In man [27] and in the horse [28] vigorous exercise has been shown to elevate 
circulating somatostatin levels, by an, as yet, unknown mechanism. Our experiences 
would seem to indicate that exercise per se is not responsible for the elevation of 
plasma SRIF-LI in the hamster since SRIF-LI did not rise in exercised food restricted 
animals unless restriction of food intake is capable of suppressing exercise induced 
SRIF-LI secretion. Fasting and starvation do reduce circulating SRIF-LI levels in 
the rat [10]. 
In conclusion, we thus believe these studies have demonstrated that the exercise- 
induced hyperphagia observed in hamsters is associated with the hyperinsulinemia, 
hypersomatotropinemia and elevation of circulating SRIF-LI which serves to mod- 
ulate the increased nutrient entry in this state. 
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